Skip to main content

Galaxy Biomedical Investment Co., Ltd. (000806.SZ)

SHZ Technology Hardware, Equipment & PartsView data quality →
52.1Fair

ValueMarkers Composite Index

Top 42%#26,067 of 44,707

DCF data not available

Piotroski
5/9
Neutral
Beneish
-2.01
Investigate
Altman
-1.01
Distress
DCF Value
-
N/A
ROIC
19.0%
Strong
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Galaxy Biomedical Investment Co., Ltd. (000806.SZ) — VMCI valuation read

The headline on Galaxy Biomedical Investment Co., Ltd. (000806.SZ) is a 52/100 VMCI score, set against a Technology sector median of 50. That 2-point above-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value tailwind is in the data.

000806.SZ insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.

**Investor frame.** 000806.SZ trades at 23.0x earnings, 28% above the Technology median of 18.0x sets the value side. ROIC of 19.0% sits 9.0pp above the Technology median (10.0%) sets the quality side. Net debt to EBITDA of 0.6x leaves covenant headroom sets the risk side, the three lines a value buyer reads first on 000806.SZ.

000806.SZ fell 1.3% over the trailing 7 days, with a +0.6% read on a 30-day basis.

Galaxy Biomedical Investment Co., Ltd. operates in the transmission and distribution, electronic information, and bio-pharmaceutical industries in China. The company produces and sells various transformer products, such as power, rectifier, and special transformers for use in metal smelting, electrochemistry, and power grid companies; and manufactures and sells electronic components, including displacement sensors, brake resistance boxes, radio frequency components, resistors, potentiometers, and others for use in aviation, aerospace, weapons, ships, AI intelligence, new energy, rail transit, communications, smart grids, instrumentation and other fields. It also offers animal products, and monoclonal antibody and targeted drugs, as well as drugs for the treatment of cancer and other diseases; laboratory equipment; and CRO, CAR-T technology and stem cell technology research and development, malignant cancer immune cell technology, and genetic testing services. The company also exports its products. The company was formerly known as Beihai Yinhe Industry Investment Co., Ltd. and changed its name to Galaxy Biomedical Investment Co., Ltd. in October 2015. Galaxy Biomedical Investment Co., Ltd. was founded in 1993 and is headquartered in Beihai, China.

CEO: Keyang Liu2,031 employeesCNwww.g-biomed.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 000806.SZ’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.